touchEXPERT OPINIONS Optimizing targeted therapy in colorectal cancer: How do the latest data impact clinical practice?
Watch three oncology experts discuss advances in targeted therapies and biomarkers for metastatic colorectal cancer (CRC).
How can we refine first-line therapy choice in mCRC? Molecular biomarkers and clinical features
Prof. Riechelmann discusses guideline-recommended biomarkers and clinical features that help guide first-line treatment choice in mCRC.
1/3 Next InterviewInterview Questions
In this interview, Prof. Riechelmann answers the following questions:
- What biomarkers and clinical features are available to refine first-line treatment selection in mCRC?
- What is the role of RAS mutational status when determining first-line treatment for mCRC?
- Presence of the BRAF-V600E mutation is a known adverse prognostic factor in mCRC: What are the molecular and clinical characteristics of this subgroup of patients?
- How does knowledge of MSI status help guide treatment choice for patients with mCRC in the first-line setting?
- How important is location of the primary tumour for first-line mCRC management?
About Prof. Rachel Riechelmann
Prof. Riechelmann is Head of Clinical Oncology at AC Camargo Cancer Center, São Paulo, Brazil. She is a medical oncologist and clinical researcher in the field of gastrointestinal (GI) and neuroendocrine tumours (NETs). read more
Prof. Riechelmann is President of the Brazilian Gastrointestinal Tumour Group (GTG), a scientific committee member of the European Society for Medical Oncology (ESMO; Colorectal and NET) and a member of the Latin American Society of GI Oncology (SLAGO). She is part of the European Society of Neuroendocrine Tumours (ENETS) Scientific Advisory Board and is Chair of the GI Latin American Cooperative Oncology Group (LACOG).
Prof. Riechelmann has published more than 100 articles in peer-reviewed journals and has authored a book titled, ‘Methods and Biostatistics in Oncology: Understanding Clinical Research as an Applied Tool’ (Springer, 2018).
Prof. Rachel Riechelmann discloses: Consulting fees from AstraZeneca, Bayer, Merck, MSD, Roche and Servier; Speakers bureau fees from Bayer, Roche and Servier; Research support from Amgen and Bayer.
How to address resistance to anti-EGFR therapy: A focus on rechallenge therapies
Dr Hanna outlines the rationale and evidence for anti-EGFR rechallenge strategies in mCRC and the potential role of liquid biopsy in this setting.
2/3 Next InterviewInterview Questions
In this interview, Dr Hanna answers the following questions:
- Why is rechallenge with anti-EGFR treatments an important strategy in mCRC?
- What mechanisms are involved in resistance to anti-EGFR therapies?
- What is the evidence for rechallenge with anti-EGFR therapies in RAS wt mCRC?
- What ongoing trials are investigating different rechallenge strategies for RAS wt mCRC?
- What is the role of liquid biopsy ctDNA testing in guiding rechallenge therapy in mCRC?
About Dr Diana Hanna
Dr Hanna is an oncology specialist practising at the Hoag Cancer Center and Keck School of Medicine, University of Southern California (USC), USA. read more
Dr Hanna earned her medical degree from the University of California, Davis, and is board-certified in internal medicine and medical oncology. She completed her Hematology/Oncology Fellowship at USC, where she served as Chief Fellow.
Dr Hanna’s research interests include investigation of predictive and prognostic biomarkers in gastrointestinal malignancies and clinical trial protocol development.
Dr Diana Hanna has no financial interests/relationships or affiliations to disclose in relation to this activity.
Treatment of BRAF-V600E-mutated mCRC: Current landscape and latest data
Prof. Yoshino discusses the challenges of treating patients with BRAF-V600E-mutated mCRC and reviews the latest clinical trial data for emerging therapies in this field.
3/3 Take CE/CME TestInterview Questions
In this interview, Prof. Yoshino answers the following questions:
- What are the challenges in the treatment of patients with BRAF-mutated mCRC?
- What is the current treatment approach for patients with BRAF-V600E-mutated mCRC?
- What are the latest data from the BEACON trial, which aims to investigate the use of BRAF, MEK, and EGFR inhibitors in BRAF-V600E-mutated mCRC in the second-line setting?
- What data are available for a combination approach using BRAF, MEK and EGFR inhibitors in BRAF-V600E-mutated mCRC in the first-line setting?
- What other potential targets are being explored for the treatment of BRAF-V600E-mutated mCRC?
About Prof. Takayuki Yoshino
Prof. Yoshino is Director of the Department of Gastroenterology and Gastrointestinal Oncology, and the Head of the Clinical Research Coordinating Division at the National Cancer Center Hospital East (NCCE) in Kashiwa, Japan. He has a particular interest in chemotherapies for gastrointestinal cancers, especially CRC, and focuses on new, investigational agents and translational research. read more
Prof. Yoshino has published more than 200 articles in peer-review journals on the topic of metastatic CRC (mCRC), with several articles published in the Lancet, Journal of Clinical Oncology, The New England Journal of Medicine and Nature Medicine.
In addition, he holds several professional appointments, serving as an International Guideline Member for the European Society of Medical Oncology (ESMO), Chair of the Pan-Asian adapted ESMO Guideline for mCRC and an American Society of Clinical Oncology (ASCO) advisory committee member. Prof. Yoshino is also part of the administrative board and is Vice Chair of the Japanese Society of Medical Oncology (JSMO) and the Japan Society of Clinical Oncology (JSCO) international affairs committees.
Prof. Takayuki Yoshino discloses: Research support from Amgen, Chugai Pharmaceutical, Daiichi Sankayo, MSD, Ono Pharmaceutical, Parexel International, Sanofi, Sumitomo Dainippon Pharma and Taiho Pharmaceutical Co. Ltd.
Overview & Learning Objectives
Overview
In this activity, three leading experts discuss the role of biomarkers in selecting first-line treatment for metastatic CRC, rechallenge strategies with anti-epidermal growth factor receptor (EGFR) therapies and the latest clinical data for BRAF-V600E-mutated tumours.
This activity has been jointly provided by Oakstone and touchIME for touchONCOLOGY. Oakstone Publishing is accredited by the ACCME to provide continuing medical education to physicians. read more
Target Audience
This activity has been designed to meet the educational needs of oncologists, including gastrointestinal specialists involved in the management of colorectal cancer, based globally.
Disclosures
Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest have been mitigated. Oakstone Publishing’s planners, content reviewers, and editorial staff disclose no relationships with ineligible entities.
Faculty
Prof. Rachel Riechelmann discloses: Consulting fees from AstraZeneca, Bayer, Merck, MSD, Roche and Servier; Speakers bureau fees from Bayer, Roche and Servier; Research support from Amgen and Bayer.
Dr Diana Hanna has no financial interests/relationships or affiliations to disclose in relation to this activity.
Prof. Takayuki Yoshino discloses: Research support from Amgen, Chugai Pharmaceutical, Daiichi Sankayo, MSD, Ono Pharmaceutical, Parexel International, Sanofi, Sumitomo Dainippon Pharma and Taiho Pharmaceutical Co. Ltd.
Content Reviewer
Walter Murray Yarbrough, MD, FACP has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Hennah Patel, MPharm, RPh, has no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing and touchIME. Oakstone Publishing is accredited by the ACCME to provide continuing medical education for physicians.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Oakstone Publishing designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive credit for this activity, participants must review and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
Date of original release: 06 May 2021. Date credits expire: 06 May 2022.
Learning Objectives
After watching this activity, participants should be better able to:
- Identify appropriate first-line therapies for patients with colorectal cancer according to the primary tumour site and molecular profile
- Discuss the rationale for rechallenge using anti-EGFR therapies and the potential treatment benefits for patients with CRC
- Analyse the most recent data for therapy for patients with BRAF-mutation-positive colorectal cancer
Register to touchONCOLOGY for FREE
- Peer reviewed journals and expert opinion
- Interactive CME and e-learning modules
- Video conference highlights
